Real Chemistry Deepens Media and Technology Edge With Acquisition of Greater Than One
Acquisition brings proprietary media planning and analytics tools into Real Chemistry's platform – enhancing strategy, performance and measurable impact for pharma and biotech clients.
Article content
NEW YORK — Real Chemistry, a leader in AI-driven insights and marketing communications for the healthcare sector, today announced it has acquired Greater Than One, an award-winning agency specializing in healthcare-first media, technology and omnichannel strategy. The acquisition brings expanded precision, stronger performance analytics and greater strategic clarity to Real Chemistry clients along every step of the commercialization journey.
Article content
'Greater Than One brings deep media expertise, powerful proprietary tools and a culture that matches ours—focused, fast-moving and built to deliver results,' said Shankar Narayanan, CEO of Real Chemistry.
'Greater Than One brings deep media expertise, powerful proprietary tools and a culture that matches ours—focused, fast-moving and built to deliver results,' said Shankar Narayanan, CEO of Real Chemistry. 'Together, we'll help clients make smarter decisions and create more meaningful engagement with the audiences who matter most. We are rewriting the next chapter of what's possible for healthcare marketing and adding Greater Than One to our team gives us even more firepower to drive this revolution.'
Article content
Precision That Drives Performance
Article content
Founded nearly 25 years ago, Greater Than One has earned a reputation for helping healthcare brands get the most from their omnichannel and media investments through a combination of data, predictive modeling and proprietary planning tools. These include:
Article content
Greater Reach, a predictive media planning engine that helps brands model budget and channel mix based on audience and engagement goals.
Greater Score, an advanced engagement scoring tool that empowers healthcare brand marketers and sales teams by providing a holistic view of healthcare professional interactions across all addressable media and CRM channels that helps marketers prioritize outreach and improve performance.
Greater Omni, Greater Than One's centralized omnichannel platform strategy and implementation capability, gives teams real-time visibility across campaigns—so clients know what's working, where to spend, and how to pivot. Their Omnichannel Maturity Model breaks the process down into clear, actionable stages – no jargon, just a roadmap to smarter engagement, better measurement and stronger returns.
Article content
These capabilities will be integrated into Real Chemistry's platform – giving clients access to unified planning, measurement and activation strategies grounded in data-driven behavioral science.
Article content
At the same time, Greater Than One clients will benefit from Real Chemistry's offerings in AI-driven strategy, creative, influencer engagement, medical communications, integrated communications and market access – unlocking a more complete and connected experience for healthcare marketers.
Article content
'This move multiplies our capability,' said Kevin Johnson, Group President and Managing Partner at Real Chemistry. 'In a healthcare environment that demands more agility and precision than ever, Greater Than One brings the technology, talent, and focus to help us deliver faster decisions, smarter planning, and measurable impact where it matters most.'
Article content
Aligned Cultures. Shared Ambition. Integrated Growth.
Article content
Greater Than One's employees will join Real Chemistry and continue operating under the brand Greater Than One, part of Real Chemistry. The agency will maintain its New York headquarters and remote-first structure.
Article content
'Finding a match like Real Chemistry, where our employees and clients will benefit, is exactly what we wanted for Greater Than One,' said Elizabeth Izard Apelles, President and CEO, Greater Than One. 'Our shared belief that building innovative, client-first partnerships leads to impact and results is a powerful force behind this acquisition.'
Article content
Terms of the transaction are not disclosed.
Article content
The acquisition builds on a year of strong momentum for Real Chemistry, which was ranked the No. 2 Healthcare Network at Cannes Lions Health 2025, named PRWeek's no. 1 PR Agency, and placed no. 3 on MM+M's Agency 100. The firm was also honored as Outstanding Healthcare Agency of the Year at the 2025 PRWeek U.S. Awards – underscoring its consistent leadership in strategy, innovation and measurable client impact in healthcare.
Article content
About Greater Than One
Article content
Greater Than One, part of Real Chemistry, is an advanced media and technology agency serving the healthcare industry. The agency delivers precision media, proprietary technology solutions, and strategic expertise to help clients navigate complexity and drive measurable growth. Greater Than One's unique technology products empowers marketers to understand customer journeys, build evidence-based strategies, forecast marketing budgets, and take actionable steps to drive prescriptions.
Article content
About Real Chemistry
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
28 minutes ago
- Globe and Mail
Can Buying $10,000 of Nvidia Stock Still Make You a Millionaire?
Key Points Nvidia would have to grow to nearly 4x last year's global GDP to turn $10,000 into $1 million. Achieving this goal is theoretically possible, but highly improbable. 10 stocks we like better than Nvidia › If you had invested $10,000 in Nvidia (NASDAQ: NVDA) on the day of its initial public offering in 1999 and never sold, you'd have a whopping $42.4 million today. Even if you had waited until 2015 to buy $10,000 of the stock and held on for the wild ride, your investment would be worth roughly $3.58 million now. But, as the old saying goes, hindsight is 20/20. Can buying $10,000 of Nvidia stock still make you a millionaire? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » What it would take Let's first address what it would take for a $10,000 investment in Nvidia to make you a millionaire. The math is simple: Since $1 million divided by $10,000 is 100, Nvidia would need to deliver a 100x gain. Most stocks aren't able to produce that kind of return, even over a lifetime. However, Nvidia has done it in less than nine years. Admittedly, it's hard to envision Nvidia doing it again. After all, the GPU maker now sports a market cap of over $4.2 trillion -- the highest valuation for any company ever. To turn $10,000 into $1 million, Nvidia's market cap would have to grow to a mind-blowing $420 trillion. To put that figure into perspective, the U.S. GDP last year was roughly $29.2 trillion. The GDP for the entire world was around $110.5 trillion. All Nvidia would have to do to make you a millionaire with a $10,000 investment is to grow to 3.8 times the economic output of every country on the planet. Easy, peasy, right? Potential scenarios It's hard to envision how Nvidia could grow 100x. However, I can come up with two potential scenarios where it could at least theoretically happen. The first scenario involves Nvidia achieving a revolutionary breakthrough that gives it a monopoly on technology that everyone wants. Maybe the company builds a teleportation device that allows people and products to be instantly transported anywhere. Perhaps a more likely goal would be to create AI superintelligence, an artificial general intelligence (AGI) system that's smarter than any human who has ever lived. Nvidia has teamed up with partners, including Turing, who are trying to develop AGI systems. The company's GEAR group (GEAR stands for "generalist embodied agent research") is trying to build foundation models, agents, and robots that might eventually achieve AGI. The second scenario requires time and consistently strong earnings growth. Nvidia's earnings jumped 31% year over year in the first quarter of 2025. Stock prices tend to track earnings growth over the long term. If we assume that Nvidia continues to grow by 31% for the next 17 or so years, its share price would increase by 100x. However, to deliver such stellar growth over such a long period, Nvidia might need a game-changing breakthrough mentioned in the first scenario. Facing long odds Is it possible that buying $10,000 of Nvidia stock right now could make you a millionaire? Sure. Is it probable? No way. The odds against Nvidia delivering a 100x gain are enormous. Of course, that's true for pretty much any other stock. However, I suspect that Nvidia could still make investors millionaires. It'll just take more money and potentially a long time. If you want $10,000 to turn into $1 million, though, you might have to find a smaller stock with tremendous growth prospects -- in other words, another Nvidia of 10 to 20 years ago. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
CBC
29 minutes ago
- CBC
With syphilis cases in N.L. on the rise, experts hope to curb numbers with increased testing
The sexually transmitted and blood-borne disease has been a growing concern for health-care professionals across the country for years. In Newfoundland and Labrador, case numbers increased by over 150 per cent over the past two years, causing those in sexual health care to promote regular testing.
Globe and Mail
38 minutes ago
- Globe and Mail
The Stock Warren Buffett Spent $78 Billion Buying Over the Last 7 Years Is Slumping, and It Begs the Question: Has the Oracle of Omaha Lost His Touch?
Key Points Warren Buffett has purchased close to $78 billion worth of his favorite stock since the midpoint of 2018 -- and you won't find it listed in Berkshire Hathaway's quarterly 13F filings. However, Berkshire's billionaire chief hasn't spent a dime buying shares of this stock for at least three quarters -- and there's a good reason why. Buffett sticking to his roots and purposefully sitting on his hands until valuations make sense shouldn't be misconstrued as weakness. 10 stocks we like better than Berkshire Hathaway › Berkshire Hathaway 's (NYSE: BRK.A)(NYSE: BRK.B) billionaire CEO Warren Buffett is widely viewed as Wall Street's greatest money manager. Without relying on fancy charting software or algorithms, the aptly named Oracle of Omaha became one of the richest people in the world and watched Berkshire grow into one of only 11 public companies worldwide to ever hit a $1 trillion valuation. Buffett's track record -- he's overseen a 5,868,186% cumulative return in Berkshire Hathaway's Class A shares (BRK.A) in six decades -- has earned him a huge following, which includes investors who aim to mirror his trading activity. But with Warren Buffett's most-purchased stock over the last seven years recently falling more than 10% as the broad-based S&P 500 and growth-fueled Nasdaq Composite power to fresh all-time highs, the question has to be asked: Has Berkshire's billionaire CEO lost his touch? Warren Buffett's favorite stock is a company near and dear to his heart Most investors track the Oracle of Omaha's buying and selling activity by following Berkshire Hathaway's quarterly Form 13F filings. This required filing for institutional investors with at least $100 million in assets under management concisely lists all buying and selling activity from the previous quarter. However, there's a catch: Buffett's favorite stock to buy isn't listed in his company's quarterly filed 13Fs. To get the skinny on this top stock, you'll need to dig into Berkshire Hathaway's quarterly operating results. On the final page of each quarterly report, just prior to the executive certifications, you'll find a detailed breakdown of exactly how much Wall Street's most-revered billionaire money manager spent on his favorite stock (cue the dramatic music)... which happens to be shares of his own company. Prior to July 2018, Warren Buffett and now-late right-hand man Charlie Munger were only allowed to repurchase shares of Berkshire Hathaway stock if it fell to or below 120% of book value (i.e., no more than 20% above listed book value). Unfortunately, Berkshire's stock never fell to or below this line-in-the-sand threshold, which resulted in no buyback activity. On July 17, 2018, Berkshire's board amended and simplified the rules governing buybacks to two criteria. It allowed the Oracle of Omaha to repurchase shares with no ceiling or end date as long as: Berkshire has at least $30 billion in combined cash, cash equivalents, and U.S. Treasuries on its balance sheet; and Buffett views shares of his company as intrinsically cheap. This latter point is purposefully vague so as to give Buffett the discretion to put his company's capital to work via buybacks whenever he feels it's appropriate. Between July 1, 2018, and March 31, 2025, Berkshire's billionaire chief bought back almost $78 billion worth of his company's shares. This is more than Buffett has spent buying Berkshire's existing stakes in Apple, Bank of America, American Express, Coca-Cola, and Chevron, combined. But the Oracle of Omaha's favorite stock is slumping. As of this writing on July 23, it's down more than 10% from its all-time closing high in early May. Perhaps more importantly, it's underperforming the benchmark S&P 500 on a year-to-date basis. Berkshire Hathaway's slump is a sign of Buffett's resolve and shouldn't be confused with weakness With Berkshire's billionaire chief set to turn 95 in less than five weeks, as well as retiring from the CEO role at the end of this year, few investors would fault him for losing his touch. But what we're witnessing with Berkshire's stock at the moment isn't a sign of Buffett failing. Rather, it's validation of his resolve and investment philosophies. During his six decades as CEO, Buffett has bent a few of his own unwritten investment rules. For instance, while he's often viewed as a long-term investor, he and his top advisors purchased shares of gaming giant Activision Blizzard in 2022 as a short-term arbitrage opportunity given Microsoft 's $95-per-share all-cash offer to acquire the company. But the one investment philosophy Warren Buffett hasn't wavered on in six decades is his desire to get a good deal. Value is of the utmost importance to Berkshire Hathaway's billionaire chief. No matter how much he appreciates a company's competitive edge, brand, and/or management team, he's not going to buy shares if the valuation doesn't make sense. When Buffett green-lit the cumulative purchase of nearly $78 billion worth of his favorite stock over 24 quarters (six years), Berkshire Hathaway stock consistently traded at a 30% to 50% premium to its book value. But between July 1, 2024, and March 31, 2025, Buffett hasn't spent a dime to repurchase his company's stock. The reason? Berkshire's premium to book climbed to between 60% and 80%. Even shares of the Oracle of Omaha's own company are off-limits when the valuation no longer makes sense. BRK.A Price to Book Value data by YCharts. However, Buffett's cold-turkey approach with his own company's stock isn't unique. He's been a net-seller of equities for 10 consecutive quarters, with $174.4 billion more in stocks sold than purchased. Back in 2001, in an interview with Fortune magazine, Buffett referred to the market-cap-to-GDP ratio as, "probably the best single measure of where valuations stand at any given moment." This valuation tool, which divides the cumulative value of all public companies by U.S. gross domestic product (GDP), has averaged a multiple of 85% when back-tested to 1970. This is to say that the aggregate value of all publicly traded stocks has equaled about 85% of U.S. GDP over 55 years. As of the closing bell on July 22, the " Buffett Indicator," as this valuation measure is now more-commonly known, hit a record high of 212.23%! Value isn't just hard to come by in this market -- it's practically nonexistent. What we're witnessing from Buffett isn't weakness. Rather, we're seeing a time-tested investor sticking to his roots and purposefully sitting on his hands until valuations make sense. Though there's no timeline as to when valuations will fall back into Warren Buffett's (or successor Greg Abel's) wheelhouse, patience has proved to be a virtue and substantial moneymaker in the past for Berkshire's CEO and the company's shareholders. Should you invest $1,000 in Berkshire Hathaway right now? Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
